# REGENXBIO Inc.

Type: Company (RGNX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/regenxbio-inc
Canonical HTML page: https://getbiobrief.com/entity/regenxbio-inc

## Recent coverage (2 stories)

### REGENXBIO CMO Sells $688K Shares After Q1 Miss, Yet Analysts See 99% Upside
2026-07-06 01:38:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Full story: https://getbiobrief.com/story/regenxbio-cmo-sells-688k-after-q1-miss-analyst-upside

### REGENXBIO Q4 Earnings Miss Highlights Gene Therapy Sector Volatility
2026-03-09 00:32:37 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

REGENXBIO reported a wider-than-expected Q4 2025 loss of $1.30 per share, missing analyst estimates of $1.01. The results reflect a broader trend of financial pressure on high-growth biotech and life science firms as they navigate late-stage clinical and commercial transitions.
Full story: https://getbiobrief.com/story/regenxbio-q4-2025-earnings-miss-gene-therapy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.